Watch CGTX. Know when insiders buy.
One email the day a filing lands. Free.
CGTX
COGNITION THERAPEUTICS INC
0.99
−0.02 −1.98%
USD · close Sep 9
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $94.1MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$16.8MNET CASH —52W 0.60 – 2.51SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$7.7M | −$3.9M | — | -0.04 | −$3.1M | — | — | Aug 7 |
| Q1 2026 · Mar 31 | — | — | — | −$8.8M | −$4.6M | — | -0.05 | −$5.5M | — | — | Aug 7 |
| Q4 2025 · Dec 31derived | — | — | — | −$13.7M | −$3.3M | — | -0.02 | −$3.4M | — | — | Aug 7 |
| Q3 2025 · Sep 30 | — | — | — | −$6.4M | −$4.9M | — | -0.06 | −$5.7M | — | — | Nov 6 |
| Q2 2025 · Jun 30 | — | — | — | −$14M | −$6.7M | — | -0.11 | −$5.6M | — | — | Aug 7 |
| Q1 2025 · Mar 31 | — | — | — | −$13.8M | −$8.5M | — | -0.14 | −$9.9M | — | — | Aug 7 |
| Q4 2024 · Dec 31derived | — | — | — | −$10.7M | −$7.8M | — | -0.17 | −$8.4M | $1K | −$8.4M | Mar 26 |
| Q3 2024 · Sep 30 | — | — | — | −$14.5M | −$9.9M | — | -0.25 | −$6.9M | $0 | −$6.9M | Nov 6 |
| Q2 2024 · Jun 30 | — | — | — | −$14.7M | −$7M | — | -0.18 | −$6M | — | — | Nov 6 |
| Q1 2024 · Mar 31 | — | — | — | −$14.1M | −$9.2M | — | -0.27 | −$7.2M | — | — | Nov 6 |
| Q4 2023 · Dec 31derived | — | — | — | −$15.2M | −$8.1M | — | -0.27 | −$5.5M | $30K | −$5.5M | Mar 20 |
| Q3 2023 · Sep 30 | — | — | — | −$14.7M | −$6.7M | — | -0.22 | −$4.2M | $58K | −$4.2M | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$47.8M | −$23.5M | — | -0.32 | −$24.6M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$54M | −$34M | — | -0.86 | −$28.5M | $4K | −$28.5M | — | — |
| FY2023 · to Dec 31 | — | — | −$50.7M | −$25.8M | — | -0.86 | −$16M | $147K | −$16.2M | — | — |
| FY2022 · to Dec 31 | — | — | −$43.6M | −$21.4M | — | -0.91 | −$18.5M | $171K | −$18.7M | — | — |
| FY2021 · to Dec 31 | — | — | −$28.6M | −$11.7M | — | -3.13 | −$3.6M | $27K | −$3.7M | — | — |
| FY2020 · to Dec 31 | — | — | −$17.4M | −$7.8M | — | -23.76 | −$3.4M | $10K | −$3.4M | — | — |
Every number comes from COGNITION THERAPEUTICS INC's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.